Cargando…
Pharmacokinetic Drug–Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese Men
BACKGROUND: Gastroprotective agents are recommended for patients receiving low-dose aspirin (LDA) or nonsteroidal anti-inflammatory drugs (NSAIDs). Vonoprazan is a potassium-competitive acid blocker recently approved for the prevention of peptic ulcer recurrence in patients receiving LDA or NSAIDs....
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209422/ https://www.ncbi.nlm.nih.gov/pubmed/27581248 http://dx.doi.org/10.1007/s40261-016-0455-2 |
_version_ | 1782490739251347456 |
---|---|
author | Sakurai, Yuuichi Shiino, Madoka Horii, Sayako Okamoto, Hiroyuki Nakamura, Koki Nishimura, Akira Sakata, Yukikuni |
author_facet | Sakurai, Yuuichi Shiino, Madoka Horii, Sayako Okamoto, Hiroyuki Nakamura, Koki Nishimura, Akira Sakata, Yukikuni |
author_sort | Sakurai, Yuuichi |
collection | PubMed |
description | BACKGROUND: Gastroprotective agents are recommended for patients receiving low-dose aspirin (LDA) or nonsteroidal anti-inflammatory drugs (NSAIDs). Vonoprazan is a potassium-competitive acid blocker recently approved for the prevention of peptic ulcer recurrence in patients receiving LDA or NSAIDs. METHODS: This phase 2, open-label, single-center study in healthy Japanese males evaluated drug–drug interactions between vonoprazan 40 mg and LDA (100 mg) or NSAIDs [loxoprofen sodium (60 mg), diclofenac sodium (25 mg), or meloxicam (10 mg)] and vice versa. Subjects were allocated to one of eight cohorts and received their orally administered treatment regimen (to assess the effect of vonoprazan vs. NSAID or LDA, or vice versa) once daily. Endpoints were the pharmacokinetics of plasma concentrations of the study drugs alone and in combination (primary), safety (secondary), and vonoprazan effects on aspirin-mediated inhibition of platelet-aggregation. RESULTS: Of 109 subjects screened, 64 were assigned to one of eight cohorts (n = 8 per cohort) and received treatment, one subject discontinued due to a treatment-emergent adverse event (TEAE), and 63 completed the study. There were few differences in the pharmacokinetics of vonoprazan when administered with LDA or NSAIDs, and few differences in the pharmacokinetics of LDA or NSAIDs when administered with vonoprazan. The differences were small and not clinically meaningful. Inhibition of arachidonic-induced platelet aggregation by LDA was not influenced by vonoprazan. Six patients experienced a TEAE, all were mild and were deemed unrelated to study drugs. One subject withdrew due to infection (tonsillitis). CONCLUSIONS: No clinically meaningful drug–drug interactions were observed and vonoprazan was well tolerated when administered with LDA or NSAIDs. STUDY REGISTRATION: JapicCTI-153100 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40261-016-0455-2) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5209422 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-52094222017-01-18 Pharmacokinetic Drug–Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese Men Sakurai, Yuuichi Shiino, Madoka Horii, Sayako Okamoto, Hiroyuki Nakamura, Koki Nishimura, Akira Sakata, Yukikuni Clin Drug Investig Original Research Article BACKGROUND: Gastroprotective agents are recommended for patients receiving low-dose aspirin (LDA) or nonsteroidal anti-inflammatory drugs (NSAIDs). Vonoprazan is a potassium-competitive acid blocker recently approved for the prevention of peptic ulcer recurrence in patients receiving LDA or NSAIDs. METHODS: This phase 2, open-label, single-center study in healthy Japanese males evaluated drug–drug interactions between vonoprazan 40 mg and LDA (100 mg) or NSAIDs [loxoprofen sodium (60 mg), diclofenac sodium (25 mg), or meloxicam (10 mg)] and vice versa. Subjects were allocated to one of eight cohorts and received their orally administered treatment regimen (to assess the effect of vonoprazan vs. NSAID or LDA, or vice versa) once daily. Endpoints were the pharmacokinetics of plasma concentrations of the study drugs alone and in combination (primary), safety (secondary), and vonoprazan effects on aspirin-mediated inhibition of platelet-aggregation. RESULTS: Of 109 subjects screened, 64 were assigned to one of eight cohorts (n = 8 per cohort) and received treatment, one subject discontinued due to a treatment-emergent adverse event (TEAE), and 63 completed the study. There were few differences in the pharmacokinetics of vonoprazan when administered with LDA or NSAIDs, and few differences in the pharmacokinetics of LDA or NSAIDs when administered with vonoprazan. The differences were small and not clinically meaningful. Inhibition of arachidonic-induced platelet aggregation by LDA was not influenced by vonoprazan. Six patients experienced a TEAE, all were mild and were deemed unrelated to study drugs. One subject withdrew due to infection (tonsillitis). CONCLUSIONS: No clinically meaningful drug–drug interactions were observed and vonoprazan was well tolerated when administered with LDA or NSAIDs. STUDY REGISTRATION: JapicCTI-153100 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40261-016-0455-2) contains supplementary material, which is available to authorized users. Springer International Publishing 2016-08-31 2017 /pmc/articles/PMC5209422/ /pubmed/27581248 http://dx.doi.org/10.1007/s40261-016-0455-2 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Research Article Sakurai, Yuuichi Shiino, Madoka Horii, Sayako Okamoto, Hiroyuki Nakamura, Koki Nishimura, Akira Sakata, Yukikuni Pharmacokinetic Drug–Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese Men |
title | Pharmacokinetic Drug–Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese Men |
title_full | Pharmacokinetic Drug–Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese Men |
title_fullStr | Pharmacokinetic Drug–Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese Men |
title_full_unstemmed | Pharmacokinetic Drug–Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese Men |
title_short | Pharmacokinetic Drug–Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese Men |
title_sort | pharmacokinetic drug–drug interactions between vonoprazan and low-dose aspirin or nonsteroidal anti-inflammatory drugs: a phase 2, open-label, study in healthy japanese men |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209422/ https://www.ncbi.nlm.nih.gov/pubmed/27581248 http://dx.doi.org/10.1007/s40261-016-0455-2 |
work_keys_str_mv | AT sakuraiyuuichi pharmacokineticdrugdruginteractionsbetweenvonoprazanandlowdoseaspirinornonsteroidalantiinflammatorydrugsaphase2openlabelstudyinhealthyjapanesemen AT shiinomadoka pharmacokineticdrugdruginteractionsbetweenvonoprazanandlowdoseaspirinornonsteroidalantiinflammatorydrugsaphase2openlabelstudyinhealthyjapanesemen AT horiisayako pharmacokineticdrugdruginteractionsbetweenvonoprazanandlowdoseaspirinornonsteroidalantiinflammatorydrugsaphase2openlabelstudyinhealthyjapanesemen AT okamotohiroyuki pharmacokineticdrugdruginteractionsbetweenvonoprazanandlowdoseaspirinornonsteroidalantiinflammatorydrugsaphase2openlabelstudyinhealthyjapanesemen AT nakamurakoki pharmacokineticdrugdruginteractionsbetweenvonoprazanandlowdoseaspirinornonsteroidalantiinflammatorydrugsaphase2openlabelstudyinhealthyjapanesemen AT nishimuraakira pharmacokineticdrugdruginteractionsbetweenvonoprazanandlowdoseaspirinornonsteroidalantiinflammatorydrugsaphase2openlabelstudyinhealthyjapanesemen AT sakatayukikuni pharmacokineticdrugdruginteractionsbetweenvonoprazanandlowdoseaspirinornonsteroidalantiinflammatorydrugsaphase2openlabelstudyinhealthyjapanesemen |